PATENT CLAIM ANALYSIS

Application Number: 15933075
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "289000"]

Abstract:
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Claim (Index 1):
A method of enhancing dextromethorphan plasma levels in a human being, comprising co-administering a bupropion with a dextromethorphan, to the human being, for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein the weight ratio between the dextromethorphan and the bupropion is about 0.4 to about 0.7, and wherein, on the eighth day that the bupropion and the dextromethorphan are co-administered, the AUC 0-12  of dextromethorphan is at least about 15 times the AUC 0-12  of dextromethorphan that would result from administering the same amount of the dextromethorphan without the bupropion for eight consecutive days.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 90.0
- Lexical Diversity: 1.45455
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15691532', '15164767', '14997316', '15688660', '15695995']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8891852160240435
- 35 USC 102 Novelty (BERT): 0.6810340764285835
- Combined Prediction Score: 0.8683701020644976
- Mean Citation Score: 783.4113140000003
- Max Citation Score: 789.3872700000003
- Similarity Product: 673.274071004162

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test